Kate Rosenbluth is the founder, chief scientific officer, and a board member of Cala Health medical technology company. Prior to this, she was the firm’s CEO. An engineer and neuroscientist, Rosenbluth previously worked on neurotherapies at Stanford Biodesign, UCSF Neurosurgery, Brainlab, Autonomic Technologies, and Genentech. As an educator, she has launched programs that include the masters of translational medicine at U.C. Berkeley and the Accel Innovation Scholars at Stanford University. Rosenbluth has authored more than 50 patents and peer-reviewed publications. She is a member of the Center for Healthcare Innovation strategy group and the McKinsey Women’s Executive Roundtable.
Previously
From revolutionary advancements aiding paralysis patients to the therapeutic treatment of PTSD, brain-computer interfaces (BCIs) possess boundless potential for merging human...